|Bid||7.24 x 200|
|Ask||7.25 x 600|
|Day's Range||7.11 - 7.35|
|52 Week Range||6.05 - 18.25|
|PE Ratio (TTM)||23.02|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The feds are investigating biomedical company MiMedx Group Inc. (MDXG) over a pair of business practices, according to Bloomberg News . Bloomberg, citing two sources it says are familiar with the matter, reported that the U.S. Justice Department is investigating whether the Marietta-based company overcharged government customers for its tissue-repair products. Investigators are also reportedly looking into MiMedx’s distribution practices, including whether the company inflated its financials by booking sales of products that hadn’t been ordered -- a practice known as channel stuffing.
The U.S. Justice Department is probing whether MiMedx overcharged the government for its tissue repair products, as well as into the company's distribution practices, the Bloomberg report said. Last week, the company said independent advisers were looking into certain sales and distribution practices at the company, and postponed its fourth-quarter financial results.
Biotech firm MiMedx Group, which jolted investors last week by delaying its year-end earnings announcement, is under U.S. Justice Department scrutiny related to a pair of business practices, according ...
MiMedx Group Inc (NASDAQ:MDXG) is trading with a trailing P/E of 26.7x, which is lower than the industry average of 27.9x. Although some investors may jump to the conclusion thatRead More...
MiMedx, a fast-growing medical tissue-graft developer, has financial ties to more than 20 doctors but hasn’t reported them to the government under a 2013 law.
In case you missed it, here are some of Benzinga's top stories from Tuesday, Feb. 20, 2018. Walmart Woes Drag Down the Dow The retail sector, as well as the broader market, traded mostly lower Tuesday ...
MiMedx Group Inc (NASDAQ: MDXG ) followed up a 6-percent sell-off on Friday with another 28-percent drop Tuesday after the company announced the postponement of its quarterly earnings results due to an ...
Did an iceberg just wallop into MiMedx Group Inc's (NASDAQ:MDXG) stock? As such, the company announced that it will postpone the release of its financial results. Block & Leviton, a securities litigation firm representing investors nationwide, is investigating whether MiMedx certain of its officers and directors violated federal securities laws following claims that the Company is engaged in a fraudulent accounting scheme and is under investigation by the SEC.
Biotech MiMedx Group Inc.'s shares were halted in premarket trade after falling 23%, for news that the company is delaying the release of fourth-quarter and full-year 2017 earnings to conduct an accounting ...
Globus Medical (GMED) is a medical device company with a focus on designing, developing, and commercializing musculoskeletal solutions. Globus Medical’s sales force is comprised of direct sales representatives and distributor sales representatives employed by exclusive independent distributors. Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating.
MiMedx Group (MDXG) operates in the regenerative biomaterials segment. MiMedx is a leading global supplier of amniotic tissue products and has supplied over a million allografts in wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.